PPARG and breast cancer: Results in these studies demonstrate that, when given alone, treatment with γ-tocotrienol, PPARγ agonists (rosiglitazone and troglitazone), or PPARγ antagonists (GW9662 and T0070907) induced a significant dose-responsive inhibition in the viability of +SA mammary tumor cells in culture.